Schonfeld Strategic Advisors’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-359,267
| Closed | -$5.65M | – | 2667 |
|
|
2024
Q1 | $5.65M | Buy |
359,267
+79,756
| +29% | +$1.23M | 0.04% | 597 |
|
|
2023
Q4 | $4.51M | Buy |
279,511
+46,611
| +20% | +$595K | 0.03% | 542 |
|
|
2023
Q3 | $2.96M | Buy |
232,900
+5,947
| +3% | +$82K | 0.02% | 705 |
|
|
2023
Q2 | $3.2M | Sell |
226,953
-20,285
| -8% | -$290K | 0.03% | 617 |
|
|
2023
Q1 | $3.82M | Buy |
247,238
+53,472
| +28% | +$893K | 0.04% | 508 |
|
|
2022
Q4 | $3.18M | Buy |
193,766
+22,629
| +13% | +$368K | 0.03% | 644 |
|
|
2022
Q3 | $3.17M | Buy |
+171,137
| New | +$2.69M | 0.03% | 695 |
|
|
2022
Q1 | – | Sell |
-14,900
| Closed | -$145K | – | 3005 |
|
|
2021
Q4 | $145K | Sell |
14,900
-79,940
| -84% | -$1.5M | ﹤0.01% | 1820 |
|
|
2021
Q3 | $3.22M | Buy |
94,840
+56,369
| +147% | +$1.8M | 0.03% | 554 |
|
|
2021
Q2 | $1.41M | Buy |
38,471
+11,375
| +42% | +$440K | 0.02% | 832 |
|
|
2021
Q1 | $1.22M | Sell |
27,096
-4,727
| -15% | -$220K | 0.01% | 820 |
|
|
2020
Q4 | $1.82M | Sell |
31,823
-1,077
| -3% | -$63.8K | 0.02% | 620 |
|
|
2020
Q3 | $1.69M | Buy |
32,900
+12,241
| +59% | +$600K | 0.03% | 558 |
|
|
2020
Q2 | $1.23M | Buy |
+20,659
| New | +$1.11M | 0.03% | 550 |
|
|
2020
Q1 | – | Sell |
-29,371
| Closed | -$1.83M | – | 1606 |
|
|
2019
Q4 | $1.83M | Buy |
+29,371
| New | +$1.4M | 0.04% | 353 |
|
|
2018
Q2 | – | Sell |
-30,146
| Closed | -$604K | – | 1018 |
|
|
2018
Q1 | $604K | Buy |
30,146
+15,146
| +101% | +$384K | 0.05% | 434 |
|
|
2017
Q4 | $340K | Sell |
15,000
-35,000
| -70% | -$685K | 0.03% | 549 |
|
|
2017
Q3 | $950K | Buy |
+50,000
| New | +$916K | 0.09% | 276 |
|
Other funds holding DCPH
Schonfeld Strategic Advisors's DCPH Position: Q2 2024 in Review
Schonfeld Strategic Advisors sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 359,267 shares — an estimated $5.65M sold.
Schonfeld Strategic Advisors first reported a position in DCPH in Q3 2017 and held it in 18 quarters. The position peaked at $5.65M in Q1 2024. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- Schonfeld Strategic Advisors reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Schonfeld Strategic Advisors sold 359,267 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $5.65M.
- Schonfeld Strategic Advisors first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 18 quarters.
- Schonfeld Strategic Advisors's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $5.65M in Q1 2024.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Schonfeld Strategic Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.